Begoña Graña

Head of Department

Complejo Hospitalario de Pontevedra

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Begoña Graña is the Head of Department at University Hospital Pontevedra (SERGAS) in Spain. Her research focuses on gastrointestinal oncology, particularly in the areas of metastatic colorectal cancer treatments and clinical guidelines. Recent publications include studies on the efficacy of aflibercept in combination with FOLFIRI and the impact of the COVID-19 pandemic on cancer patient survival.

Articles (9)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Collaborators (4)

Enrique Aranda Aguilar

Profesor Titular de Universidad

Universidad de Córdoba

SPAIN

View details

VEGA IRANZO GONZALEZ-CRUZ

Profesora Asociada Universitaria

University of Valencia

SPAIN

View details

Judith Balmaña

Head

Hospital Universitari Vall d'Hebron

SPAIN

View details

Ana M. Ayuso-Alvarez

Instituto de Salud Carlos III

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Begoña Graña

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

<i>Nab</i> -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer

Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial.

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study.

SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

Do Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method

Collaborators (4)

Enrique Aranda Aguilar

VEGA IRANZO GONZALEZ-CRUZ

Judith Balmaña

Ana M. Ayuso-Alvarez

Make your next move.